Spots Global Cancer Trial Database for Study Evaluating Etanercept in Moderate to Severe Asthma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study Evaluating Etanercept in Moderate to Severe Asthma
Official Title: A Randomized, Double-Blind, Placebo Controlled Trial Evaluating the Safety and Efficacy of Etanercept 25mg Twice Weekly in Subjects With Moderate to Severe Persistent Asthma
Study ID: NCT00141791
Conditions
Interventions
Study Description
Brief Summary: The primary objective of the study is to assess the efficacy and safety of etanercept 25 mg given twice weekly in subjects with moderate to severe persistent asthma.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
, Birmingham, Alabama, United States
, Denver, Colorado, United States
, Sarasota, Florida, United States
, Tallahassee, Florida, United States
, Valrico, Florida, United States
, Covington, Louisiana, United States
, Wheaton, Maryland, United States
, Boston, Massachusetts, United States
, Rockville Center, New York, United States
, Winston-Salem, North Carolina, United States
, Portland, Oregon, United States
, Richmond, Virginia, United States
, Madison, Wisconsin, United States
Contact Details
Name: Medical Monitor
Affiliation: Wyeth is now a wholly owned subsidiary of Pfizer
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
